Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00743 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Mark Sabat und 30 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Drug Discovery Unit, Takeda Development Center Americas, Inc., 9625 Towne Centre Dr., San Diego, California 92121 United States. Hauptthemen laut MEDLINE: Drug Design, Receptors, Vitronectin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Takeda Pharmaceutical Company.
Abstract (Originalsprache)
Selective inhibition of the RGD (Arg-Gly-Asp) integrin αvβ1 has been recently identified as an attractive therapeutic approach for the treatment of liver fibrosis given its function, target expression, and safety profile. Our identification of a non-RGD small molecule lead followed by focused, systematic changes to the core structure utilizing a crystal structure, in silico modeling, and a tractable synthetic approach resulted in the identification of a potent small molecule exhibiting a remarkable affinity for αvβ1 relative to several other integrin isoforms measured. Azabenzimidazolone 25 demonstrated antifibrotic efficacy in an in vivo rat liver fibrosis model and represents a tool compound capable of further exploring the biological consequences of selective αvβ1 inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gastroenterology Drug Discovery Unit, Takeda Development Center Americas, Inc., 9625 Towne Centre Dr., San Diego, California 92121 United States.
ORCID-Profile: Daniel W Carney, Tony S Gibson, Rui Xu, Simone V Bigi-Botterill, Lucas K Johnson, Lily Kwok, Kevin DeMent, Andrew C Flick
Förderung
- Takeda Pharmaceutical Company
Zitieren
APA
Sabat, M., Carney, D. W., Hernandez-Torres, G., Gibson, T. S., Balakrishna, D., Zou, H., Xu, R., Chen, C. H., de Jong, R., Dougan, D. R., Qin, L., Bigi-Botterill, S. V., Chambers, A., Miura, J., Johnson, L. K., Ermolieff, J., Johns, D., Selimkhanov, J., Kwok, L., …, & Flick, A. C. (2024). Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00743
Vancouver
Sabat M, Carney DW, Hernandez-Torres G, Gibson TS, Balakrishna D, Zou H, et al. Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00743
BibTeX
@article{Sabat2024,
author = {Sabat, Mark and Carney, Daniel W and Hernandez-Torres, Gloria and Gibson, Tony S and Balakrishna, Deepika and Zou, Hua and Xu, Rui and Chen, Chien-Hung and de Jong, Ron and Dougan, Douglas R and Qin, Ling and Bigi-Botterill, Simone V and Chambers, Alison and Miura, Joanne and Johnson, Lucas K and Ermolieff, Jacques and Johns, Deidre and Selimkhanov, Jangir and Kwok, Lily and DeMent, Kevin and Proffitt, Chris and Vu, Phong and Lindsey, Erick A and Ivetac, Tony and Jennings, Andy and Wang, Haixia and Manam, Padma and Santos, Cipriano and Fullenwider, Cody and Manohar, Rohan and Flick, Andrew C},
title = {Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00743}
}
EUVIMED